Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis

Firefly Neuroscience, Inc. AIFF announced a collaboration with Bright Minds Biosciences Inc. DRUG to analyze data from the first-in-human Phase 1 study of BMB-101, Bright Minds’ lead compound for neuropsychiatric disorders and refractory epilepsy. Firefly employed its advanced AI-powered BNA technology to analyze the qEEG (Quantitative Electroencephalogram) data collected through EEG headsets provided by Zeto Inc.

Why It Matters: The study demonstrated positive results, with subjects undergoing EEG recordings pre- and post-dose on days 1 and 7. The data showed that BMB-101 successfully achieved brain penetration, validating its targeting of 5-HT2C receptors. With the successful conclusion of the Phase 1 study, BMB-101 is now set to move into Phase 2 trials.

Jon Olsen, CEO of Firefly, emphasized the impact of their AI platform on clinical studies, while Ian McDonald, CEO of Bright Minds, confirmed the company's plans to advance BMB-101 with an investigative new drug submission.

A Growing Trend In The Market

Firefly continues to advance strategic partnerships and introducing technology into the market. The company recently announced a collaboration with Ketamine Clinics Los Angeles which will combine immersive digital mindfulness experiences with evidence-based therapies for conditions such as depression and PTSD. FireflyVR’s platform, The Sanctuary, offers dynamic VR environments that engage patients through guided mindfulness exercises such as breathings, body scans and meditations.

Cover image made with AI